Paxman AB (PAX) AI Stock Analysis

• Market Cap: kr1.07B
• Dividend Yield: N/A
• Average Volume (3M): 100.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: 21.71%
• EPS Growth: -80.37%
• Country: SE
• Employees: 105
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.40
• Shares Outstanding: 23,273,417
• 10 Day Avg. Volume: 41,338
• 30 Day Avg. Volume: 100,373
• PEG Ratio: 0.54
• Price to Book (P/B): 3.05
• Price to Sales (P/S): 3.95
• P/FCF Ratio: -145.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.81
• Revenue Forecast (FY): kr465.65M

• Rating: 56 Neutral
• Price Target: kr47.00 ▼(-13.60% Downside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

The score is driven primarily by mixed financial performance—strong balance-sheet resilience and ongoing revenue growth are offset by a sharp 2025 margin/earnings breakdown and uneven cash generation. Technical indicators are moderately supportive in the near term, but valuation is pressured by losses and a negative P/E.

Positive Factors

Strong balance sheet

A conservative capital structure with very low leverage and materially larger equity provides resilience to fund placements, absorb shocks, and invest in distribution or product support. This supports long-term optionality and reduces solvency risk when scaling installed base.

Negative Factors

Severe margin deterioration

A dramatic collapse in gross margin erodes core profitability and questions unit economics of product and consumable sales. If structural, it impairs capacity to fund R&D, service, and sales expansion and weakens operating leverage even if revenue keeps growing.

Paxman AB Business Overview & Revenue Model

Company Description

Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Cent...

Read more

Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Cent...

How the Company Makes Money

Paxman makes money primarily by selling and/or leasing its scalp cooling systems to healthcare providers (e.g., hospitals and oncology clinics) and by generating recurring revenue tied to ongoing use of those systems. Key revenue streams typically...

Read more

Paxman makes money primarily by selling and/or leasing its scalp cooling systems to healthcare providers (e.g., hospitals and oncology clinics) and by generating recurring revenue tied to ongoing use of those systems. Key revenue streams typically...

Paxman AB Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	313.35M	253.01M	210.12M	156.75M	96.20M
Gross Profit	4.26M	175.42M	146.42M	101.44M	64.52M
EBITDA	28.46M	49.73M	31.23M	16.18M	1.25M
Net Income	-16.71M	40.20M	8.33M	-10.32M	-12.78M
Balance Sheet
Total Assets	479.11M	227.23M	167.12M	173.96M	166.34M
Cash, Cash Equivalents and Short-Term Investments	120.83M	40.31M	24.98M	38.09M	72.27M
Total Debt	13.01M	14.29M	13.57M	16.98M	17.15M
Total Liabilities	73.95M	63.24M	44.51M	59.76M	40.59M
Stockholders Equity	405.16M	163.99M	122.62M	114.20M	125.75M
Cash Flow
Free Cash Flow	-8.50M	15.99M	-9.70M	-33.01M	-27.94M
Operating Cash Flow	6.23M	39.10M	15.63M	2.69M	-4.14M
Investing Cash Flow	-32.35M	-24.50M	-25.33M	-36.69M	-24.45M
Financing Cash Flow	108.83M	721.00K	-3.41M	-169.00K	97.28M

Paxman AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 54.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PAX, the sentiment is Negative. The current price of 54.4 is above the 20-day moving average (MA) of 46.05, above the 50-day MA of 47.74, and below the 200-day MA of 62.68, indicating a neutral trend. The MACD of -0.67 indicates Negative momentum. The RSI at 45.83 is Neutral, neither overbought nor oversold. The STOCH value of 12.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PAX.

Paxman AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PAX	56 Neutral	kr1.07B	-74.03	-4.20%	―	21.71%	-80.37%
CRAD.B	55 Neutral	kr915.08M	103.06	6.93%	―	-5.80%	-65.99%
SEZI	52 Neutral	kr719.26M	-5.78	-36.55%	―	62.24%	21.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRAIN	50 Neutral	kr252.72M	-4.05	-27.22%	―	16.38%	35.71%
OSSD	47 Neutral	kr387.19M	-24.57	―	―	38.43%	57.76%
SEDANA	44 Neutral	kr921.85M	-17.24	-4.42%	―	13.48%	28.98%